Abata Therapeutics

Executive Director, Medical Affairs – APAC Regional Head

Remote

Not SpecifiedCompensation
Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
BiotechnologyIndustries

Position Overview

  • Location Type: Remote
  • Employment Type: Full-time
  • Salary: Not specified

Dianthus Therapeutics is a publicly traded, clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases. To learn more, please visit www.dianthustx.com and follow us on LinkedIn.

This role, the Regional Head of Medical and Clinical Affairs, will lead and oversee the company’s medical affairs strategy and activities across the APAC region. Reporting to the Global Head of Medical Affairs, you will be responsible for driving medical excellence, supporting clinical development, ensuring scientific communication, and fostering relationships with key opinion leaders (KOLs), healthcare professionals (HCPs), and patient advocacy groups. You will play a crucial role in shaping the company's growth in the APAC market and ensuring alignment with regulatory and healthcare organizations. Experience in clinical development and medical affairs is ideal to support Phase II/III programs through commercialization. This is a unique opportunity to join an effort to bring a best in class complement inhibitor to patients in need, and to build Dianthus presence and capabilities in the region. We are building a culture of individuals who hold our core principles at the center of our operations, with the goal to elevate the care of our patients’ lives. We are open to you working remotely.

Requirements

  • Experience in clinical development and medical affairs is ideal to support Phase II/III programs through commercialization.
  • Strong understanding of the pharmaceutical industry and regulatory landscape.
  • Excellent communication, interpersonal, and presentation skills.
  • Ability to build and maintain relationships with KOLs, HCPs, and patient advocacy groups.

Responsibilities

  • Medical Strategy Development & Execution:
    • Lead the development and execution of the APAC medical affairs strategy in alignment with global objectives.
    • Provide medical insights to support business and regulatory decisions.
    • Collaborate with cross-functional teams (clinical development, clinical operations, regulatory affairs, commercial, and market access) to ensure scientific alignment and strategic focus.
  • Scientific & Medical Communication:
    • Ensure the dissemination of accurate, balanced, and scientifically sound medical information.
    • Lead the development and approval of scientific publications, presentations, and other communication materials.
    • Represent the company at key scientific and medical conferences and engage with external stakeholders.
  • KOL & Stakeholder Engagement:
    • Develop and maintain relationships with top regional KOLs, HCPs, and patient advocacy groups across APAC region.
    • Engage in meaningful dialogue with external experts to gather insights, and feedback, and strengthen partnerships.
    • Act as the primary point of contact for key stakeholders in the region.
  • Clinical Development & Support:
    • Provide medical expertise to support ongoing clinical trial activities.

Application Instructions

  • Not specified. (Please refer to Dianthus Therapeutics' website for application details.)

Skills

Medical Affairs
Clinical Development
Scientific Communication
KOL Engagement
HCP Relationship Management
Regulatory Knowledge
Autoimmune and Inflammatory Diseases

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters
2021Year Founded
$184.8MTotal Funding
EARLY_VCCompany Stage
BiotechnologyIndustries
11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.
Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.
Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.
Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.
Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.
FDA's accelerated approval pathways may expedite Abata's clinical trials.
Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI